From: Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
Whole cohort (n = 150) Mean ± SD or n and (%) | n | |
---|---|---|
Characteristics | ||
Age, years | 63.3 ± 14.5 | 150 |
Height, cm | 166.3 ± 8.7 | 149 |
Weight, kg | 78.0 ± 16.8 | 150 |
Body mass index | 28.2 ± 5.7 | 149 |
Sex, female | 93 (62) | 149 |
6-min walking distance | 331 ± 126 | 118 |
WHO functional class | 130 | |
II | 25 (19.2) | |
III | 90 (69.2) | |
IV | 15 (11.6) | |
PAH classification | ||
Idiopathic PAH | 44 (29.3) | 150 |
heritable PAH | 4 (2.7) | |
Associated PAH | 50 (33.4) | |
Other PAH* | 52 (34.7) | |
PAH therapy | ||
Monotherapy | 98 (65.3%) | 150 |
Double combination | 50 (33.3%) | |
Triple combination | 2 (1.4%) | |
PAH medication | ||
Calcium channel blocker | 12 (8.0%) | 150** |
Endothelin receptor antagonist | 62 (41.3%) | |
Phosphodiesterase 5 inhibitor | 116 (77.3%) | |
Prostacyclin | 2 (1.3%) | |
Soluble guanylate cyclase stimulator | 7 (4.8%) | |
Laboratory | ||
Creatinine, mg/dl | 1.05 ± 0.42 | 149 |
Glomerular filtration rate, % | 69.2 ± 25.2 | 143 |
Iron, µg/dl | 13.9 ± 6.7 | 74 |
Hemoglobin, g/dl | 14.5 ± 1.8 | 149 |
Iron deficiency | 40 (54.1) | 74 |
Hemoglobin deficiency | 16 (10.7) | 149 |
Ferritin < 40, ng/ml | 13 (16.0) | 81 |
MCV < 83, fl | 21 (14.1) | 149 |
MCH < 27, pg/cell | 17 (11.4) | 149 |
MCHC < 30, g/dl | 6 (4.0) | 149 |
Hypochromic erythrocytes > 2% | 21 (33.9) | 62 |
Diffusion capacity | ||
DLCO SB, % | 48.7 ± 22.3 | 130 |
Echocardiography | ||
Right atrial area, cm2 | 20.5 ± 6.3 | 142 |
Right ventricular area, cm2 | 24.4 ± 7.1 | 145 |
Systolic pulmonary arterial pressure, mmHg | 63.6 ± 19.5 | 147 |
Tricuspid annular plane systolic excursion | 1.9 ± 0.6 | 146 |
Right heart catheter | ||
Right atrial pressure, mmHg | 8.0 ± 4.7 | 111 |
Mean pulmonary arterial pressure, mmHg | 43.7 ± 12.4 | 150 |
Cardiac output, l/min | 4.6 ± 1.3 | 134 |
Pulmonary arterial wedge pressure, mmHg | 9.7 ± 3.1 | 143 |
Pulmonary vascular resistance, dynes*sec*cm−1 | 651 ± 323 | 142 |